• TRM (USD/COP)COP 3,235.59 +1.65% +COP 52.60Colombia's official exchange rate (Financial Superintendence), valid Nov 4 to Nov 4
  • EuroCOP 3,617.08 +1.72% +COP 61.02Reference: TRM crossed with the European Central Bank rate of Nov 3; not the market quote
  • Mexican pesoCOP 173.98 +3.35% +COP 5.64Reference: TRM crossed with the European Central Bank rate of Nov 3; not the market quote

Moderna falls 17.6% despite positive data from its cancer vaccine

FinanceInternationalXTB.com40 s readAI summary
Image: XTB.com

Moderna shares fell 17.6% to US$202.63 after phase 3 data for intismeran autogene, its personalized cancer vaccine developed with Merck, leaked early. The trial, with 1,137 high-risk melanoma patients, showed a 42% reduction in the risk of recurrence or death when combined with Keytruda, versus 49% in phase 2b. The market had expected a more convincing confirmation. The stock is up 587.1% in 2026.

In 40 seconds

  • Moderna lost 17.6% and closed at US$202.63 after the leak of phase 3 data for its cancer vaccine.
  • The combination with Keytruda reduced the risk of recurrence or death by 42% and the risk of distant metastasis or death by 38% in 1,137 high-risk melanoma patients.
  • Phase 2b had shown reductions of 49% and 59%, benchmarks the market used for comparison despite differences between the studies.
Read the full story at XTB.com

IASummary generated by artificial intelligence from a story by XTB.com. It may contain errors: the original source prevails.

Comments

Be respectful. Comments reported by several people are hidden until a moderator reviews them.

You do not need an account to read, only to comment. Sign in with a code sent to your email or with your Google account. We only show the name you choose, never your email.

    Keep reading